

FILSPARI[®] (sparsentan)

2-Year Results from the Phase 3 PROTECT Study Published in *The Lancet*

The 2-year results of efficacy and safety data from the Phase 3 PROTECT Study evaluating sparsentan in adults with IgA nephropathy (IgAN) was published in *The Lancet*. Please [click here](#) to consent to the Sunshine Act reporting requirements and to receive access to the publication. If you would like to access the article directly from *The Lancet*, please [click here](#).

The PROTECT Study is one of the largest interventional studies to date in IgA nephropathy (IgAN) and the only head-to-head trial in this rare kidney disease. It is a global, randomized, multicenter, double-blind, parallel-arm, active-controlled clinical trial evaluating the safety and efficacy of 400 mg of sparsentan, compared to 300 mg of irbesartan, in 404 patients ages 18 years and up with IgAN and persistent proteinuria despite receiving at least 50% of max label dose and maximally tolerated ACEi or ARB therapy.

Sincerely,

Traverse Therapeutics Medical Information